These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 9345340

  • 1. Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
    Iop A, Cartei G, Vigevani E, Clocchiatti L, Mansutti M, Sibau AM.
    Am J Clin Oncol; 1997 Oct; 20(5):515-8. PubMed ID: 9345340
    [Abstract] [Full Text] [Related]

  • 2. Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
    Bensmaine M el-A, Guillot T, Bernal ET, Janot F, Sigal R, Domenge C, Wibault P, Armand JP, Cvitkovic E.
    Am J Clin Oncol; 1996 Aug; 19(4):356-62. PubMed ID: 8677904
    [Abstract] [Full Text] [Related]

  • 3. Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer.
    Alba E, Sanchez-Chaparro MA, Alonso L, Ribelles N, Ramon Delgado J, Rueda A, Pablo Tenllado P, Solano J, Urquiza R.
    Am J Clin Oncol; 1996 Apr; 19(2):140-3. PubMed ID: 8610637
    [Abstract] [Full Text] [Related]

  • 4. Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial.
    Kish JA, Wolf MK, Schellhammer PF, Hussain MH, Einstein AB, Crawford ED.
    Am J Clin Oncol; 1997 Aug; 20(4):327-30. PubMed ID: 9256883
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
    Riva C, Lavieille JP, Schmerber S, Cuisnie O, Reyt E.
    Int J Oncol; 2000 Sep; 17(3):543-9. PubMed ID: 10938396
    [Abstract] [Full Text] [Related]

  • 6. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
    Schena M, Barone C, Birocco N, Dongiovanni D, Numico G, Colantonio I, Bertetto O.
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):271-6. PubMed ID: 15592837
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma.
    Tellez-Bernal E, Belehradek M, Recondo G, Cvitkovic E, Leridant AM, Vericel R, Armand JP.
    Am J Clin Oncol; 1990 Oct; 13(5):452-4. PubMed ID: 1699403
    [Abstract] [Full Text] [Related]

  • 8. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD, Trichas M, Stavrinidis E, Roupakia A, Ioannidou G, Kritselis G, Liossi P, Giannakouras G, Douzinas EE, Katsilieris I.
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [Abstract] [Full Text] [Related]

  • 9. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, Wang X, Kapp AV, Royer-Joo S, Penuel E, McCall B, Pirzkall A, Clement PM.
    Cancer; 2016 Dec 15; 122(24):3803-3811. PubMed ID: 27525588
    [Abstract] [Full Text] [Related]

  • 10. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
    Caponigro F, Comella P, Marcolin P, Russo Spena F, Biglietto M, Cartenì G, De Lucia L, Avallone A, Gravina A, Comella G.
    Cancer; 1999 Feb 15; 85(4):952-9. PubMed ID: 10091775
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
    Kohno N, Kitahara S, Tamura E, Tanabe T, Nakanoboh M, Kawada M, Shirasaka T.
    Gan To Kagaku Ryoho; 2000 May 15; 27 Suppl 2():592-9. PubMed ID: 10895216
    [Abstract] [Full Text] [Related]

  • 13. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
    Kucuk O, Shevrin DH, Pandya KJ, Bonomi PD.
    Am J Clin Oncol; 2000 Aug 15; 23(4):371-5. PubMed ID: 10955866
    [Abstract] [Full Text] [Related]

  • 14. Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
    Kohno N, Kitahara S, Tamura E, Tanabe T.
    Oncology; 2002 Aug 15; 63(3):226-31. PubMed ID: 12381901
    [Abstract] [Full Text] [Related]

  • 15. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].
    Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, Elias D, Eschwege F.
    Bull Cancer; 1999 Oct 15; 86(10):861-5. PubMed ID: 10572237
    [Abstract] [Full Text] [Related]

  • 16. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
    Caponigro F, Rosati G, De Rosa P, Avallone A, De Rosa V, De Lucia L, Comella P, Comella G.
    Oncology; 2002 Oct 15; 63(3):232-8. PubMed ID: 12381902
    [Abstract] [Full Text] [Related]

  • 17. Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
    Amrein PC, Fabian RL.
    Laryngoscope; 1992 Aug 15; 102(8):901-6. PubMed ID: 1379664
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
    Hitt R, Jimeno A, Millán JM, Castellano D, Cortés-Funes H.
    Cancer; 2004 Aug 15; 101(4):768-75. PubMed ID: 15305408
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Hussain M, Benedetti J, Smith RE, Rodriguez GI, Schuller D, Ensley J.
    Cancer; 1995 Oct 01; 76(7):1233-7. PubMed ID: 8630903
    [Abstract] [Full Text] [Related]

  • 20. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
    Chi KH, Chan WK, Shu CH, Law CK, Chen SY, Yen SH, Chen KY.
    Cancer; 1995 Dec 01; 76(11):2186-92. PubMed ID: 8635020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.